Fulcrum Therapeutics (NASDAQ:FULC) Downgraded by Cantor Fitzgerald

Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics (NASDAQ:FULC – Free Report) from an overweight rating to a neutral rating in a research note published on Thursday morning, Marketbeat Ratings reports. Several other research firms have also recently issued reports on FULC. Bank of America raised shares of Fulcrum Therapeutics from an underperform rating to a […]

Leave a Reply

Your email address will not be published.

Previous post AMREP (NYSE:AXR) Posts Quarterly Earnings Results
Next post Lovesac (NASDAQ:LOVE) Updates FY 2025 Earnings Guidance